[1] HUANG W，LIN Y S，MCCONN D J，et al. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism[J] . Drug Metab Dispos，2004，32(12)： 1434-1445. [2] KAMDEM L K，STREIT F，ZANGER U M，et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus[J] . Clini Chem，2005，51(8)： 1374-1381. [3] KIM R B，LEAKE B F，CHOO E F，et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans[J] . Clin Pharmacol Ther，2001，70(2)： 189-199. [4] SAKAEDA T，NAKAMURA T，OKUMURA K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs[J] . Pharmacogenomics，2003，4(4)： 397-410. [5] HOFFMEYER S，BURK O，VON RICHTER O，et al. Functional polymorphisms of the human multidrug-resistance gene：multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo[J] . Proc Natl Acad Sci USA，2000， 97(7)：3473-3478. [6] HU Y F，HE J，CHEN G L，et al. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population[J] . Clini Chim Acta，2005，353(1-2)： 187-192. [7] VENKATARAMANAN R，SWAMINATHAN A，PRASAD T，et al. Clinical pharmacokinetics of tacrolimus[J] . Clin Pharmacokinet，1995，29(6)： 404-430. [8] WALLEMACQ P E, VERBEEDK R K. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients[J] . Clin Pharmacokinet，2001，40(4)： 283-295. [9] MANCINELLI L M, FRASSETTO L, FLOREN L C, et al. The pharmacokinetics and metabolic disposition of tacrolimus： a comparison across ethnic groups[J] . Clin Pharmacol Ther，2001，69(1)： 24-31. [10] KUEHL P，ZHANG J，LIN Y，et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression[J] . Nat Genet，2001，27(4)：383-391. [11] SIMPSON D，NOBLE S. Tacrolimus ointment： a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions[J] . Drugs，2005，65(6)：827-858. [12] ZHENG H，ZEEVI A，SCHUETZ E，et al. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism[J] . J Clin Pharmacol，2004，44(2)： 135-140. [13] ZHANG X，LIU Z，ZHENG J M，et al. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation[J] . Clin Transplant，2005，19(5)： 638-643. [14] ZHENG H，WEBBER S，ZEEVI A，et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms[J] . Am J Transplant，2003，3(4)： 477-483. [15] FUKUDO M, YANO I, MASUDA S, et al. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients[J] . Clin Pharmacol Ther，2006，80(4)： 331-345. [16] GOTO M，MASUDA S，KIUCHI T，et al. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation[J] . Pharmacogenetics，2004，14(7)： 471-478. [17] UESUGI M, MASUDA S, KATSURA T，et al. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients[J] . Pharmacogenet Genomics，2006，16(2)： 119-127. [18] YU S F，WU L H，JIN J，et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation[J] . Transplantation，2006，81(1)： 46-51. [19] WANG W L, JIN J, ZHENG S S，et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients[J] . Liver Transplantation，2006，12(5)：775-780. [20] MASUDA S, GOTO M, OKUDA M，et al. Initial dosage adjustment for oral administration of tacrolimus using the intestinal MDR1 level in living-donor liver transplant recipients[J] . Transplant Proc，2005，37(4)： 1728-1729